產(chǎn)品屬性：
產(chǎn)品名稱 | QLT0267 |
規(guī)格 | 5 mg、10 mg、25 mg |
貨號(hào) | EY-01Y10830 |
Cas No.: 866409-68-9
別名: N/A
化學(xué)名: N/A
分子式: C10H12N6O
分子量: 232.2
溶解度: DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: slightly soluble
儲(chǔ)存條件: -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
QLT0267 is an inhibitor of integrin-linked kinase (ILK; IC50 = 26 nM).1 It is greater than 10-fold selective for ILK over cyclin-dependent kinase 1 (Cdk1), Cdk2, and Cdk5, as well as greater than 1,000-fold selective for ILK over C-terminal Src kinase (CSK), DNA-PK, Pim-1, Akt, PKC, and casein kinase 2 (CK2), at 10 mg/ml. QLT0267 inhibits the growth of NPA187 papillary thyroid cancer cells (IC50 = ~3 μM) and induces apoptosis in NPA187, DRO, and K4 cancer cell lines. In vivo, QLT0267 (100 mg/kg) reduces tumor growth in a DRO mouse xenograft model. It also reduces tumor volume and intratumoral blood vessel mass in a U87MG glioblastoma mouse xenograft model.2 1.Younes, M.N., Kim, S., Yigitbasi, O.G., et al.Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancerMol. Cancer. Ther.4(8)1146-1156(2005)
2.Edwards, L.A., Woo, J., Huxham, L.A., et al.Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK)Mol. Cancer Ther.7(1)59-70(2008)
特別提醒公司產(chǎn)品僅供科研使用
